Spironolactone	spironolactone	CHEMICALS	O	OTHERS	I
:	:	O	O	O	O
is	is	O	O	O	O
it	it	O	O	O	O
a	a	O	O	O	O
novel	novel	O	O	O	O
drug	drug	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
prevention	prevention	O	O	O	O
of	of	O	O	O	O
amphotericin	amphotericin	CHEMICALS	O	OTHERS	I
B-related	b-related	O	O	O	O
hypokalemia	hypokalemia	O	O	OTHERS	I
in	in	O	O	O	O
cancer	cancer	O	DISEASE	OTHERS	I
patients?OBJECTIVE	patients?objective	O	O	O	O
:	:	O	O	O	O
Nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
is	is	O	O	O	O
the	the	O	O	O	O
major	major	O	O	O	O
adverse	adverse	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
amphotericin	amphotericin	CHEMICALS	O	OTHERS	I
B	b	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
AmB	amb	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
often	often	O	O	O	O
limiting	limiting	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
full	full	O	O	O	O
dosage	dosage	O	O	O	O
.	.	O	O	O	O

Selective	selective	O	O	O	O
distal	distal	O	O	O	O
tubular	tubular	O	O	O	O
epithelial	epithelial	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
seems	seems	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
responsible	responsible	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
profound	profound	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
wasting	wasting	O	O	O	O
that	that	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
major	major	O	O	O	O
clinical	clinical	O	O	O	O
side	side	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
AmB.	amb.	O	O	O	O
Potassium	potassium	CHEMICALS	O	OTHERS	I
depletion	depletion	O	O	O	O
also	also	O	O	O	O
potentiates	potentiates	O	O	O	O
the	the	O	O	O	O
tubular	tubular	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
AmB.	amb.	O	O	O	O
This	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
designed	designed	O	O	O	O
to	to	O	O	O	O
assess	assess	O	O	O	O
the	the	O	O	O	O
ability	ability	O	O	O	O
of	of	O	O	O	O
spironolactone	spironolactone	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
reduce	reduce	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
requirements	requirements	O	O	O	O
and	and	O	O	O	O
to	to	O	O	O	O
prevent	prevent	O	O	O	O
hypokalemia	hypokalemia	O	O	OTHERS	I
in	in	O	O	O	O
neutropenic	neutropenic	O	O	OTHERS	I
patients	patients	O	O	O	O
on	on	O	O	O	O
AmB	amb	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
26	26	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
various	various	O	O	O	O
hematological	hematological	O	O	OTHERS	I
disorders	disorders	O	O	OTHERS	I
were	were	O	O	O	O
randomized	randomized	O	O	O	O
to	to	O	O	O	O
receive	receive	O	O	O	O
either	either	O	O	O	O
intravenous	intravenous	O	O	O	O
AmB	amb	CHEMICALS	O	OTHERS	I
alone	alone	O	O	O	O
or	or	O	O	O	O
AmB	amb	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
oral	oral	O	O	O	O
spironolactone	spironolactone	CHEMICALS	O	OTHERS	I
100	100	O	O	O	O
mg	mg	O	O	OTHERS	I
twice	twice	O	O	O	O
daily	daily	O	O	O	O
when	when	O	O	O	O
developing	developing	O	O	O	O
a	a	O	O	O	O
proven	proven	O	O	O	O
or	or	O	O	O	O
suspected	suspected	O	O	O	O
fungal	fungal	O	O	OTHERS	I
infection	infection	O	DISEASE	OTHERS	I
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
concomitant	concomitant	O	O	O	O
AmB	amb	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
spironolactone	spironolactone	CHEMICALS	O	OTHERS	I
had	had	O	O	O	O
significantly	significantly	O	O	O	O
higher	higher	O	O	O	O
plasma	plasma	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
than	than	O	O	O	O
those	those	O	O	O	O
receiving	receiving	O	O	O	O
AmB	amb	CHEMICALS	O	OTHERS	I
alone	alone	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
=	=	O	O	O	O
0.0027	0.0027	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Those	those	O	O	O	O
patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
AmB	amb	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
spironolactone	spironolactone	CHEMICALS	O	OTHERS	I
required	required	O	O	O	O
significantly	significantly	O	O	O	O
less	less	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
supplementation	supplementation	O	O	O	O
to	to	O	O	O	O
maintain	maintain	O	O	O	O
their	their	O	O	O	O
plasma	plasma	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
within	within	O	O	O	O
the	the	O	O	O	O
normal	normal	O	O	O	O
range	range	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
=	=	O	O	O	O
0.022	0.022	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Moreover	moreover	O	O	O	O
,	,	O	O	O	O
urinary	urinary	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
losses	losses	O	O	O	O
were	were	O	O	O	O
significantly	significantly	O	O	O	O
less	less	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
AmB	amb	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
spironolactone	spironolactone	CHEMICALS	O	OTHERS	I
than	than	O	O	O	O
those	those	O	O	O	O
receiving	receiving	O	O	O	O
AmB	amb	CHEMICALS	O	OTHERS	I
alone	alone	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
=	=	O	O	O	O
0.040	0.040	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
This	this	O	O	O	O
study	study	O	O	O	O
showed	showed	O	O	O	O
that	that	O	O	O	O
spironolactone	spironolactone	CHEMICALS	O	OTHERS	I
can	can	O	O	O	O
reduce	reduce	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
requirements	requirements	O	O	O	O
and	and	O	O	O	O
prevent	prevent	O	O	O	O
hypokalemia	hypokalemia	O	O	OTHERS	I
by	by	O	O	O	O
reducing	reducing	O	O	O	O
urinary	urinary	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
loss	loss	O	O	O	O
in	in	O	O	O	O
neutropenic	neutropenic	O	O	OTHERS	I
patients	patients	O	O	O	O
on	on	O	O	O	O
AmB	amb	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
.	.	O	O	O	O

